Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
Remo Panaccione(University of Calgary), Julián Panés(Hospital Clínic de Barcelona), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Samuel I. Anyanwu(AbbVie (United States)), Elena Dubcenco(AbbVie (United States)), Efrat Broide(Assaf Harofeh Medical Center), Feng Tian(Sun Yat-sen University), Scott D. Lee(University of Washington), Stijn van Haaren(AbbVie (United States)), Miguel Regueiro(University of Pittsburgh Medical Center), Ana P. Lacerda(AbbVie (United States)), Cristina Rodríguez(Universidad de Navarra), Gitte Pedersen(Aarhus University), Ziqian Geng(AbbVie (United States)), Tao Wang(Kunming University of Science and Technology), Adriaan A. van Bodegraven(Zuyderland Medisch Centrum)
Cited by 4
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669